BR112022012281A2 - Combinações - Google Patents

Combinações

Info

Publication number
BR112022012281A2
BR112022012281A2 BR112022012281A BR112022012281A BR112022012281A2 BR 112022012281 A2 BR112022012281 A2 BR 112022012281A2 BR 112022012281 A BR112022012281 A BR 112022012281A BR 112022012281 A BR112022012281 A BR 112022012281A BR 112022012281 A2 BR112022012281 A2 BR 112022012281A2
Authority
BR
Brazil
Prior art keywords
combinations
disease
compounds
condition
inhibitor
Prior art date
Application number
BR112022012281A
Other languages
English (en)
Portuguese (pt)
Inventor
Abdi Samatar Ahmed
Li Jiali
Izadi Hooman
Qinhua Huang Peter
Clayton Boren Brant
Robert Pinchman Joseph
Duane Bunker Kevin
Donate Fernando
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of BR112022012281A2 publication Critical patent/BR112022012281A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
BR112022012281A 2019-12-20 2020-12-16 Combinações BR112022012281A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962952039P 2019-12-20 2019-12-20
PCT/US2020/065409 WO2021127044A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
BR112022012281A2 true BR112022012281A2 (pt) 2022-08-30

Family

ID=76478095

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012281A BR112022012281A2 (pt) 2019-12-20 2020-12-16 Combinações

Country Status (12)

Country Link
US (1) US20230008362A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069235A4 (cg-RX-API-DMAC7.html)
JP (1) JP7631348B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119442A (cg-RX-API-DMAC7.html)
CN (1) CN115427042A (cg-RX-API-DMAC7.html)
AU (1) AU2020407070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012281A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165472A1 (cg-RX-API-DMAC7.html)
IL (1) IL294080A (cg-RX-API-DMAC7.html)
MX (1) MX2022007626A (cg-RX-API-DMAC7.html)
TW (1) TW202132299A (cg-RX-API-DMAC7.html)
WO (1) WO2021127044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183776A1 (en) 2014-05-29 2015-12-03 Merck Sharp & Dohme Corp. Methods for treating cancer with a wee1 inhibitor
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ

Also Published As

Publication number Publication date
IL294080A (en) 2022-08-01
EP4069235A4 (en) 2024-01-10
WO2021127044A1 (en) 2021-06-24
EP4069235A1 (en) 2022-10-12
MX2022007626A (es) 2022-09-23
CN115427042A (zh) 2022-12-02
KR20220119442A (ko) 2022-08-29
AU2020407070A1 (en) 2022-07-14
JP7631348B2 (ja) 2025-02-18
US20230008362A1 (en) 2023-01-12
CA3165472A1 (en) 2021-06-24
JP2023508328A (ja) 2023-03-02
TW202132299A (zh) 2021-09-01

Similar Documents

Publication Publication Date Title
BR112022012280A2 (pt) Combinações
BR112022012283A2 (pt) Combinações
BR112022012278A2 (pt) Combinações
BR112022012266A2 (pt) Combinações
BR112022023254A2 (pt) Monoterapias e terapias de combinação
PT3883579T (pt) Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
BR112019007144A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX2022007626A (es) Combinaciones.
WO2015184145A8 (en) Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CO2024009571A2 (es) Inhibidores de parp1
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX382765B (es) Tratamiento para la colangitis biliar primaria.
BR112017013982A2 (pt) fármaco de combinação
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2020012253A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona para el tratamiento del carcinoma quistico adenoide.
BR112022009066A2 (pt) Ezetimiba para uso em tratamento de câncer
BR112022009035A2 (pt) Fármaco de combinação

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]